Swiss biopharmaceutical company Legacy Healthcare announced on Tuesday that it is planning to advance its topical solution, Cinainu, into a multi-regional Phase 3 trial (RAAINBOW-2) for moderate to severe alopecia areata (AA).
The US Food and Drug Administration (FDA) has cleared the company's IND filing for Cinainu, allowing the botanical drug-candidate to proceed with an international Phase 3 study in patients with moderate to severe AA for New Drug Application (NDA) purpose.
FDA clearance follows the successful international Phase 2/3 study (RAAINBOW) in children and adolescents with moderate-to-severe AA, and the agreement from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) on the conduct of a global Phase 3 trial including Japanese adult and paediatric patients (from age 2) to support registration in Japan. Discussions with other health authorities to extend the Phase 3 RAAINBOW-2 trial to additional regions will follow.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval